Evaluation of phosphodiesterase 9A as a novel biomarker in heart failure with preserved ejection fraction-Reference-Cited by-同舟云学术

Evaluation of phosphodiesterase 9A as a novel biomarker in heart failure with preserved ejection fraction

Published:2021-03-30 Issue:3 Volume:8 Page:1861-1872
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Besler Christian¹,Rommel Karl‐Philipp¹,Kresoja Karl‐Patrik¹,Mörbitz Justus¹,Kirsten Holger²³,Scholz Markus²³,Klingel Karin⁴,Thiery Joachim³⁵,Burkhardt Ralph³⁶,Büttner Petra¹,Adams Volker⁷,Thiele Holger¹,Lurz Philipp¹

Affiliation:

1. Department of Internal Medicine/Cardiology Heart Center Leipzig at University of Leipzig Strümpellstraße 39 Leipzig 04289 Germany

2. Institute for Medical Informatics, Statistics and Epidemiology University of Leipzig Leipzig Germany

3. LIFE Research Center for Civilization Diseases University of Leipzig Leipzig Germany

4. Cardiopathology, Institute for Pathology and Neuropathology University Hospital Tübingen Tübingen Germany

5. Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics University Hospital Leipzig Leipzig Germany

6. Institute of Clinical Chemistry and Laboratory Medicine University Hospital Regensburg Regensburg Germany

7. Department of Internal Medicine and Cardiology Technische Universität Dresden Dresden Germany

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ehf2.13327

Reference27 articles.

1. Heart Failure With Preserved Ejection Fraction Expert Panel Report

2. Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved ejection fraction;Martin N;Cochrane Database Syst Rev,2018

3. Heart failure with preserved ejection fraction: from mechanisms to therapies

4. Cyclic Guanosine Monophosphate Signaling and Phosphodiesterase-5 Inhibitors in Cardioprotection

5. Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathophysiological insights into HFpEF from studies of human cardiac tissue;Nature Reviews Cardiology;2024-08-28

2. Heart Failure With Preserved Ejection Fraction in the Elderly Population: Basic Mechanisms and Clinical Considerations;Canadian Journal of Cardiology;2024-08

3. The role of phosphodiesterase 9A inhibitors in heart failure;Expert Opinion on Investigational Drugs;2024-05-08

4. Screening and identification of key biomarkers associated with endometriosis using bioinformatics and next generation sequencing data analysis;2024-05-08

5. Transthyretin amyloid cardiomyopathy among patients with heart failure and preserved ejection fraction: the AMY score;ESC Heart Failure;2024-04-13